Incanthera PLC (AQSE:INC) announced it has received positive data from a skin sensitisation study of its skin cancer technology Sol.

Sol is a proprietary topical formulation designed to deliver into the skin an active known to prevent the formation of solar (actinic) keratosis and skin cancer.

READ: Incanthera delighted as Sol outshines rivals in new study

Formerly, studies carried out in collaboration between XCellR8 and Cutest, a clinical research organisation with expertise in trials using topical applications, have demonstrated “very good correlation” between results using the methodology of this study and those obtained in clinical mildness studies.

Sol’s “non-irritancy” was found to be comparable to baby sun protection products tested previously, Incanthera said, with Sol scoring better those products which they would define as “very mild”.

The specialist oncology firm said it is delighted with the results, which demonstrate that Sol is “non-irritant”.

The comfort and safety of human skin’s reaction to the topical application of Sol is a further valuable marker of the asset and this technology, it added.

“This additional positive data on Sol, greatly enhances the product’s overall profile and supports our ongoing negotiations with potential commercial partners,” said chairman Tim McCarthy in a statement.